Turn Therapeutics Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Turn Therapeutics Inc. (TTRX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$322.98 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-12
- Turn Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $290.49K, a 21.67% decline year-over-year.
- Turn Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$613.46K.
- Turn Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $664.30K, a 1213.27% increase year-over-year.
- Turn Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $1.25M.
- Turn Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $2.26M, a 1015.95% increase from fiscal 2024.
- Turn Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $202.65K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $290.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$322.98K 10-Q · filed 2026-08-12 | $341.33K derived: sum of 3 quarters · filed 2026-08-12 | $1.59M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$613.46K 10-Q · filed 2026-05-11 | $50.84K derived: sum of 2 quarters · filed 2026-05-11 | $1.30M derived: sum of 3 quarters · filed 2026-05-11 | $1.67M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $664.30K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.91M derived: sum of 2 quarters · filed 2026-03-31 | $2.28M derived: sum of 3 quarters · filed 2026-08-12 | $2.26M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.62M derived: sum of 2 quarters · filed 2026-08-12 | $1.60M 10-Q · filed 2025-11-13 | $1.65M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $370.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $350.07K 10-Q · filed 2026-08-12 | $400.66K derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-03-31 | -$20.77K 10-Q · filed 2026-05-11 | $29.82K derived: sum of 2 quarters · filed 2026-05-11 | ||
| 2024-12-31 | $50.58K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $202.65K 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $152.06K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |